Skip to main content

Silexion Therapeutics Corp 10-Q for FY2026 Q3

Silexion Therapeutics Corp (SLXN)

10-Q 2026-11-12 For: 2026-09-30
View Original
Added on November 12, 2026

About this 10-Q

Silexion Therapeutics Corp filed this 10-Q on November 12, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Silexion Therapeutics Corp dosed its first SIL204 Phase 2/3 patient in locally advanced pancreatic cancer, while awaiting a Nasdaq listing decision. The company reported an $8.8 million nine-month net loss and said cash would fund only several months. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net loss
$2.53M
compared with a net loss of $3.26M a year earlier
Diluted EPS
$13.70
down 98.0% from $691.14 a year earlier